CoChat
Sign Up
Cited by 120

Kymriah® (tisagenlecleucel) - an overview of the clinical development journey of the first approved CAR-T therapy

Awasthi, Rakesh, Maier, Harald J., Zhang, Jie, Lim, Stephen·2023·Human Vaccines & Immunotherapeutics
DOI 10.1080/21645515.2023.2210046PMC PMC10294746
Open this paper in CoChat — free account

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1080/21645515.2023.2210046

Cites

1 of 1 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • Tisagenlecleucel (Kymriah®) was the first cell-based gene therapy approved by the US FDA and in 34 other countries, yet it is not approved in Scotland.

    “For example, Tisagenlecleucel (Kymriah®) was the first cell-based gene therapy approved by the US FDA and in 34 other countries (Awasthi et al., 2023), yet it is not approved in Scotland.”

    From Brief summary of the regulatory frameworks of regenerative medicine therapies (2025) · cites this paper as Awasthi et al., 2023

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Cites

Flagged first, then by citations

Research works printed but not linked: 45

  1. [1]Rives S, Maude SL, Hiramatsu H, Baruchel A, Bader P, Bittencourt H, Buechner J, Laetsch T, De Moerloose B, Qayed M, et al. Tisagenlecleucel in pediatric and young adult patients (Pts) with relapsed/refractory (R/R) B-cell acute lymphoblastic leukemia (B-All): final analyses from the eliana study. HemaSphere. 2022; 6: 1– 8. doi: 10.1097/01.HS9.0000843344.19780.98. · DOI
  2. [2]Schuster SJ, Tam CS, Borchmann P, Worel N, McGuirk JP, Holte H, Waller EK, Jaglowski S, Bishop MR, Damon LE, et al. Long-term clinical outcomes of tisagenlecleucel in patients with relapsed or refractory aggressive B-cell lymphomas (JULIET): a multicentre, open-label, single-arm, phase 2 study. Lancet Oncol. 2021; 22: 1403– 15. doi: 10.1016/S1470-2045(21)00375-2. 34516954 · DOI
  3. [4]Tyagarajan S, Spencer T, Smith J. Optimizing CAR-T cell manufacturing processes during pivotal clinical trials. Mol Ther Methods Clin Dev. 2020; 16: 136– 44. doi: 10.1016/j.omtm.2019.11.018. 31988978 PMC6970133 · DOI · Paper page
  4. [5]Maude SL, Laetsch TW, Buechner J, Rives S, Boyer M, Bittencourt H, Bader P, Verneris MR, Stefanski HE, Myers GD, et al. Tisagenlecleucel in children and young adults with B-cell lymphoblastic leukemia. N Engl J Med. 2018; 378: 439– 48. doi: 10.1056/NEJMoa1709866. 29385370 PMC5996391 · DOI · Paper page
  5. [7]John S, Pulsipher MA, Moskop A, Z-H H, Phillips CL, Hall EM, Margossian SP, Nikiforow S, Martin PL, Oshrine B, et al. Real-world outcomes for pediatric and young adult patients with relapsed or refractory (R/R) B-cell acute lymphoblastic leukemia (ALL) treated with tisagenlecleucel: update from the Center for International Blood and Marrow Transplant Research (CIBMTR) registry. Blood. 2021; 138: 428.
  6. [8]Crump M, Neelapu SS, Farooq U, Van Den Neste E, Kuruvilla J, Westin J, Link BK, Hay A, Cerhan JR, Zhu L, et al. Outcomes in refractory diffuse large B-cell lymphoma: results from the international SCHOLAR-1 study. Blood. 2017; 130: 1800– 8. doi: 10.1182/blood-2017-03-769620. 28774879 PMC5649550 · DOI
  7. [9]Den Neste E V, Schmitz N, Mounier N, Gill D, Linch D, Trneny M, Milpied N, Radford J, Ketterer N, Shpilberg O, et al. Outcome of patients with relapsed diffuse large B-cell lymphoma who fail second-line salvage regimens in the International CORAL study. Bone Marrow Transplant. 2016; 51: 51– 7. doi: 10.1038/bmt.2015.213. 26367239 · DOI
  8. [10]Link BK, Day BM, Zhou X, Zelenetz AD, Dawson KL, Cerhan JR, Flowers CR, Friedberg JW. Second-line and subsequent therapy and outcomes for follicular lymphoma in the United States: data from the observational national lymphoCare study. Br J Haematol. 2019; 184: 660– 3. doi: 10.1111/bjh.15149. 29611177 · DOI
  9. [11]Landsburg DJ, Frigault M, Heim M, Foley SR, Hill BT, Ho CM, Jacobson CA, Jaglowski S, Locke FL, Ram R, et al. Real-world outcomes for patients with relapsed or refractory (R/R) aggressive B-cell non-hodgkin’s lymphoma (aBNHL) treated with commercial tisagenlecleucel: subgroup analyses from the Center for International Blood and Marrow Transplant Research (CIBMTR) registry. Blood. 2022; 140: 1584– 7.
  10. [12]Riedell PA, Hwang WT, Nastoupil LJ, Pennisi M, McGuirk JP, Maziarz RT, Bachanova V, Oluwole OO, Brower J, Flores OA, et al. Patterns of use, outcomes, and resource utilization among recipients of commercial axicabtagene ciloleucel and tisagenlecleucel for relapsed/refractory aggressive B cell lymphomas. Transplant Cell Ther. 2022; 28: 669– 76. doi: 10.1016/j.jtct.2022.07.011. 35850429 PMC9547952 · DOI
  11. [13]Bishop MR, Dickinson M, Purtill D, Barba P, Santoro A, Hamad N, Kato K, Sureda A, Greil R, Thieblemont C, et al. Second-line tisagenlecleucel or standard care in aggressive B-cell lymphoma. N Engl J Med. 2022; 386: 629– 39. doi: 10.1056/NEJMoa2116596. 34904798 · DOI
  12. [14]Pinnix CC, Gunther JR, Dabaja BS, Strati P, Fang P, Hawkins MC, Adkins S, Westin J, Ahmed S, Fayad L, et al. Bridging therapy prior to axicabtagene ciloleucel for relapsed/refractory large B-cell lymphoma. Blood Adv. 2020; 4: 2871– 83. doi: 10.1182/bloodadvances.2020001837. 32589728 PMC7362355 · DOI
  13. [15]Roschewski M, Longo DL, Wilson WH. CAR T-cell therapy for large B-cell lymphoma - who, when, and how? N Engl J Med. 2022; 386: 692– 6. doi: 10.1056/NEJMe2118899. 34904797 PMC9295142 · DOI · Paper page
  14. [16]Frigault MJ, Dietrich J, Gallagher K, Roschewski M, Jordan JT, Forst D, Plotkin SR, Cook D, Casey KS, Lindell KA, et al. Safety and efficacy of tisagenlecleucel in primary CNS lymphoma: a phase 1/2 clinical trial. Blood. 2022; 139: 2306– 15. doi: 10.1182/blood.2021014738. 35167655 PMC9012129 · DOI
  15. [17]Brudno JN, Kochenderfer JN. Toxicities of chimeric antigen receptor T cells: recognition and management. Blood. 2016; 127: 3321– 30. doi: 10.1182/blood-2016-04-703751. 27207799 PMC4929924 · DOI
  16. [18]Wang Z, Han W. Biomarkers of cytokine release syndrome and neurotoxicity related to CAR-T cell therapy. Biomark Res. 2018; 6: 4. doi: 10.1186/s40364-018-0116-0. 29387417 PMC5778792 · DOI
  17. [19]Grupp SA, Kalos M, Barrett D, Aplenc R, Porter DL, Rheingold SR, Teachey DT, Chew A, Hauck B, Wright JF, et al. Chimeric antigen receptor–Modified T cells for acute lymphoid leukemia. N Engl J Med. 2013; 368: 1509– 18. doi: 10.1056/NEJMoa1215134. 23527958 PMC4058440 · DOI · Paper page
  18. [20]Porter D, Frey N, Wood PA, Weng Y, Grupp SA. Grading of cytokine release syndrome associated with the CAR T cell therapy tisagenlecleucel. J Hematol Oncol. 2018; 11: 35. doi: 10.1186/s13045-018-0571-y. 29499750 PMC5833070 · DOI
  19. [21]Lee DW, Gardner R, Porter DL, Louis CU, Ahmed N, Jensen M, Grupp SA, Mackall CL. Current concepts in the diagnosis and management of cytokine release syndrome. Blood. 2014; 124: 188– 95. doi: 10.1182/blood-2014-05-552729. 24876563 PMC4093680 · DOI · Paper page
  20. [22]Lee DW, Santomasso BD, Locke FL, Ghobadi A, Turtle CJ, Brudno JN, Maus MV, Park JH, Mead E, Pavletic S, et al. ASTCT consensus grading for cytokine release syndrome and neurologic toxicity associated with immune effector cells. Biol Blood Marrow Transplant. 2019; 25: 625– 38. doi: 10.1016/j.bbmt.2018.12.758. 30592986 PMC12180426 · DOI · Paper page
  21. [23]Schuster SJ, Maziarz RT, Rusch ES, Li J, Signorovitch JE, Romanov VV, Locke FL, Maloney DG. Grading and management of cytokine release syndrome in patients treated with tisagenlecleucel in the JULIET trial. Blood Adv. 2020; 4: 1432– 9. doi: 10.1182/bloodadvances.2019001304. 32271899 PMC7160283 · DOI
  22. [24]Maziarz RT, Schuster SJ, Romanov VV, Rusch ES, Li J, Signorovitch JE, Maloney DG, Locke FL. Grading of neurological toxicity in patients treated with tisagenlecleucel in the JULIET trial. Blood Adv. 2020; 4: 1440– 7. doi: 10.1182/bloodadvances.2019001305. 32271898 PMC7160265 · DOI
  23. [25]Santomasso BD, Nastoupil LJ, Adkins S, Lacchetti C, Schneider BJ, Anadkat M, Atkins MB, Brassil KJ, Caterino JM, Chau I, et al. management of immune-related adverse events in patients treated with chimeric antigen receptor T-cell therapy: ASCO guideline. J Clin Oncol. 2021; 39: 3978– 92. doi: 10.1200/JCO.21.01992. 34724386 · DOI
  24. [26]Bear AS, Morgan RA, Cornetta K, June CH, Binder-Scholl G, Dudley ME, Feldman SA, Rosenberg SA, Shurtleff SA, Rooney CM, et al. Replication-competent retroviruses in gene-modified T cells used in clinical trials: is it time to revise the testing requirements? Mol Ther. 2012; 20: 246– 9. doi: 10.1038/mt.2011.288. 22297819 PMC3277217 · DOI · Paper page
  25. [27]Levine BL, Miskin J, Wonnacott K, Keir C. Global manufacturing of CAR T cell therapy. Mol Ther Methods Clin Dev. 2017; 4: 92– 101. doi: 10.1016/j.omtm.2016.12.006. 28344995 PMC5363291 · DOI · Paper page
  26. [28]Awasthi R, Pacaud L, Waldron E, Tam CS, Jager U, Borchmann P, Jaglowski S, Foley SR, van Besien K, Wagner-Johnston ND, et al. Tisagenlecleucel cellular kinetics, dose, and immunogenicity in relation to clinical factors in relapsed/refractory DLBCL. Blood Adv. 2020; 4: 560– 72. doi: 10.1182/bloodadvances.2019000525. 32045475 PMC7013261 · DOI
  27. [29]Mueller KT, Waldron E, Grupp SA, Levine JE, Laetsch TW, Pulsipher MA, Boyer MW, August KJ, Hamilton J, Awasthi R, et al. Clinical pharmacology of tisagenlecleucel in B-cell acute lymphoblastic leukemia. Clin Cancer Res. 2018; 24: 6175– 84. doi: 10.1158/1078-0432.CCR-18-0758. 30190371 PMC7433345 · DOI
  28. [30]Melenhorst JJ, Chen GM, Wang M, Porter DL, Chen C, Collins MA, Gao P, Bandyopadhyay S, Sun H, Zhao Z, et al. Decade-long leukaemia remissions with persistence of CD4(+) CAR T cells. Nature. 2022; 602: 503– 9. doi: 10.1038/s41586-021-04390-6. 35110735 PMC9166916 · DOI
  29. [31]Awasthi R, Mueller KT, Yanik GA, Tam CS, Rives S, McGuirk JP, Pulsipher MA, Boyer MW, Jaeger U, Baruchel A, et al. Evaluation of in vivo CAR transgene levels in relapsed/refractory pediatric and young adult ALL and adult DLBCL tisagenlecleucel-treated patients. Blood. 2018; 132: 899. doi: 10.1182/blood-2018-99-116385. · DOI
  30. [32]Pasquini MC, Hu ZH, Curran K, Laetsch T, Locke F, Rouce R, Pulsipher MA, Phillips CL, Keating A, Frigault MJ, et al. Real-world evidence of tisagenlecleucel for pediatric acute lymphoblastic leukemia and non-Hodgkin lymphoma. Blood Adv. 2020; 4: 5414– 24. doi: 10.1182/bloodadvances.2020003092. 33147337 PMC7656920 · DOI
  31. [33]Stefanski H, Eaton A, Baggott C, Rossoff J, Verneris MR, Prabhu S, Pacenta HL, Phillips CL, Talano JA, Moskop A, et al. Higher doses of tisagenlecleucel associate with improved outcomes: a report from the pediatric real-world CAR consortium. Blood Adv. 2023; 7: 541– 548. doi: 10.1182/bloodadvances.2022007246. 35938863 PMC9979765 · DOI
  32. [34]Schultz LM, Baggott C, Prabhu S, Pacenta HL, Phillips CL, Rossoff J, Stefanski HE, Talano J-A, Moskop A, Margossian SP, et al. Disease burden affects outcomes in pediatric and young adult B-cell lymphoblastic leukemia after commercial tisagenlecleucel: a pediatric real-world chimeric antigen receptor consortium report. J Clin Oncol. 2022; 40: 945– 55. doi: 10.1200/JCO.20.03585. 34882493 PMC9384925 · DOI
  33. [35]Schuster SJ, Svoboda J, Chong EA, Nasta SD, Mato AR, Anak O, Brogdon JL, Pruteanu-Malinici I, Bhoj V, Landsburg D, et al. Chimeric antigen receptor T cells in refractory B-cell lymphomas. N Engl J Med. 2017; 377: 2545– 54. doi: 10.1056/NEJMoa1708566. 29226764 PMC5788566 · DOI
  34. [36]Pulsipher MA, Han X, Maude SL, Laetsch TW, Qayed M, Rives S, Boyer MW, Hiramatsu H, Yanik GA, Driscoll T, et al. Next-generation sequencing of minimal residual disease for predicting relapse after tisagenlecleucel in children and young adults with acute lymphoblastic leukemia. Blood Cancer Discov. 2022; 3: 66– 81. doi: 10.1158/2643-3230.BCD-21-0095. 35019853 PMC9924295 · DOI
  35. [37]Flinn IW, Jaeger U, Shah NN, Blaise D, Briones J, Shune L, Boissel N, Bondanza A, Lu D, Zhu X, et al. A first-in-human study of YTB323, a novel, autologous CD19-directed CAR-T cell therapy manufactured using the novel T-Charge TM platform, for the treatment of patients (Pts) with relapsed/refractory (r/r) diffuse large B-cell lymphoma (DLBCL). Blood. 2021; 138: 740. doi: 10.1182/blood-2021-146268. · DOI
  36. [38]Keating SJ, Gu T, Jun MP, McBride A. Health care resource utilization and total costs of care among patients with diffuse large B cell lymphoma treated with chimeric antigen receptor T cell therapy in the United States. Transplant Cell Ther. 2022; 28: 404 e1– e6. doi: 10.1016/j.jtct.2022.03.021. 35354101 · DOI
  37. [39]Maziarz RT, Yang H, Liu Q, Wang T, Zhao J, Lim S, Lee S, Dalal A, Bollu V. Real-world healthcare resource utilization and costs associated with tisagenlecleucel and axicabtagene ciloleucel among patients with diffuse large B-cell lymphoma: an analysis of hospital data in the United States. Leuk Lymphoma. 2022; 63: 2052– 62. doi: 10.1080/10428194.2022.2060503. 35422192 · DOI
  38. [40]Chimeric antigen receptor T-cell therapy for B-cell cancers: effectiveness and value. Institute for Clinical and Economic Review; 2018 Mar 23.
  39. [41]Hao Y, Eldjerou LK, Yang H, Qi C, Globe D. Cost-effectiveness analysis of CTL019 for the treatment of pediatric and young adult patients with relapsed or refractory B-cell acute lymphoblastic leukemia in the United States. Blood. 2017; 130: 609.
  40. [42]Lin JK, Lerman BJ, Barnes JI, Boursiquot BC, Tan YJ, Robinson AQL, Davis KL, Owens DK, Goldhaber-Fiebert JD. Cost effectiveness of chimeric antigen receptor T-cell therapy in relapsed or refractory pediatric B-cell acute lymphoblastic leukemia. J Clin Oncol. 2018; 36: 3192– 202. doi: 10.1200/JCO.2018.79.0642. 30212291 · DOI
  41. [43]Roth JA, Sullivan SD, Lin VW, Bansal A, Purdum AG, Navale L, Cheng P, Ramsey SD. Cost-effectiveness of axicabtagene ciloleucel for adult patients with relapsed or refractory large B-cell lymphoma in the United States. J Med Econ. 2018; 21: 1238– 45. doi: 10.1080/13696998.2018.1529674. 30260711 · DOI
  42. [44]Whittington MD, McQueen RB, Ollendorf DA, Kumar VM, Chapman RH, Tice JA, Pearson SD, Campbell JD. Long-term survival and value of chimeric antigen receptor T-cell therapy for pediatric patients with relapsed or refractory leukemia. JAMA Pediatr. 2018; 172: 1161– 8. doi: 10.1001/jamapediatrics.2018.2530. 30304407 PMC6583018 · DOI
  43. [45]Baumgardner J, Everson K, Brauer M, Zhang J, Hao Y, Liu J, Lakdawalla DN. CAR-T therapy displays favorable gains in health outcomes and competitive cost-effectiveness when compared with past innovative cancer treatments. Blood. 2018; 132: 322. doi: 10.1182/blood-2018-99-116763. · DOI
  44. [46]Snider JT, Brauer M, Batt K, Karaca-Mandic P, Zhang J, Goldman DP. The social value of tisagenlecleucel, a CAR-T cell therapy, for the treatment of relapsed or refractory pediatric acute lymphoblastic leukemia in the United States: what are consequences of treatment delays? J Clin Oncol. 2018; 36: 10529. doi: 10.1200/JCO.2018.36.15_suppl.10529. · DOI
  45. [47]Neelapu SS, Jacobson CA, Ghobadi A, Miklos DB, Lekakis LJ, Oluwole OO, Lin Y, Braunschweig I, Hill BT, Timmerman JM, et al. 5-year follow-up supports curative potential of axicabtagene ciloleucel in refractory large B-cell lymphoma (ZUMA-1). Blood. 2023. doi: 10.1182/blood.2022018893. 36821768 · DOI

Cited by

Sorted by citations

Authors
Awasthi, R., Maier, H. J., Zhang, J., & Lim, S.
Affiliations
  • Novartis Institutes for BioMedical Research
  • Novartis Pharma AG
  • Novartis Services Inc
  • Novartis Pharmaceuticals Corporation
Venue
Human Vaccines & Immunotherapeutics
Publisher
Informa UK Limited
Published
2023-01-02
Volume
19
Issue
1
ISSN
  • 2164-5515
  • 2164-554X
DOI
10.1080/21645515.2023.2210046
PMC
PMC10294746
Cited by
120
References
1
Language
en
Licence
creativecommons.org/licenses/by-nc-nd/4.0/ (vor)
Funders
no funding

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review